The cancer antibody conjugate market is rapidly expanding, highlighted by increased patent filings and clinical trials. Key opportunities include strategic positioning in antibody, linker, and payload ...

Designing modular, automated vial fill-finish lines that balance high-output demands with small-batch precision in an Annex 1 ...

Raubling, Germany Friday, February 20, 2026, 17:00 Hrs [IST] ...

Advances in instrumentation, modeling and control are more fully understood and utilized when assisted by first-principle, ...

A cube of healthy bone is anything but solid. Inside it, countless tiny channels carry fluid and help cells move, feed, and ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

In this GEN webinar, experts from ChemPartner, Philip Clarke, PhD, Hu Liu, PhD, and Greg Liang, MD, will provide an overview of some of the innovative platforms that are shaping the next-generation of ...

Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Daiichi Sankyo recently reported several developments, including European Medicines Agency validation of a Type II variation filing for ENHERTU in early‑stage HER2 positive breast cancer, a new ...

Once the active ingredient is defined, an Applicant must select which patent, or patents, to put forward for extension. The statute permits only one PTE per regulatory review period, so the choice is ...

Treating brain diseases like tumors and Alzheimer's is notoriously difficult due to the blood-brain barrier (BBB), which blocks most drugs. While nanomedicine offers a promising solution, its path to ...